[1] Brahmer J R, Lacchetti C, Schneider B J,et al. Management of in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline[J].JCO,2018, 36(17):1714-1768.
[2] Muntyanu A, Netchiporouk E, Gerstein W, et al. Cutaneous immune-related adverse (irAEs) eventsto immune checkpoint inhibitors: a dermatology perspective on management[J]. J Cutan Med Surg, 2021, 25(1): 59-76.
[3] Coleman E, Ko C, Dai F,et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management[J]. J Am Acad Dermatol, 2019, 80(4): 990-997.
[4] Ullmann A J, Aguado J M,Arikan-Akdagli S,et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J].Clin Microbiol Infect, 2018,24(Suppl 1):e1-e38.
[5] Micha B, Pawe P, Justyna S,et al.Early diagnosis and treatment of invasive aspergillosis as a main determinant of outcome-review of literature according to the presented case report[J]. Ann Agric Environ Med, 2017, 24(1): 100-103.
[6] 韩天栋, 宋 健, 田 野. 住院医师规范性培训中辩证思维能力的培养[J].医学与哲学,2020,41(8): 26-29.
[7] Siegel J, Totonchy M, Damsky W, et al.Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy[J]. J Am Acad Dermatol, 2018, 79(6): 1081-1088.
[8] Jour G, Glitza I C, Ellis R M, et al.Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions[J]. J CutanPathol, 2016, 43(8): 688-696.
[9] Lopez A T, Khanna T, Antonov N,et al. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors[J]. Int J Dermatol, 2018, 57(6): 664-669.
[10] Dulos J, Carven G J, Van Boxtel S J, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer[J]. J Immunother, 2012, 35(2): 169-178.
[11] 吴家睿. 临床指南在精确医学时代面临的挑战[J].医学与哲学,2021,42(3): 6-9.
[12] Naidoo J, Schindler K, Querfeld C, et al.Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1[J]. Cancer Immunol Res, 2016, 4(5): 383-389.
[13] Dai J, Belum V R, Wu S, et al. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis[J]. J Am Acad Dermatol, 2017, 77(5): 902-910.
[14] Hywel C W, Fenella W, Gudula K,et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial[J]. Lancet, 2017, 389(10079): 1630-1638.
[15] Jacob S, Mariam T, William D, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy [J]. J Am Acad Dermatol, 2018, 79(6): 1081-1088.